BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 17426205)

  • 1. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
    Kaira K; Oriuchi N; Otani Y; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Endo K; Mori M
    Chest; 2007 Apr; 131(4):1019-27. PubMed ID: 17426205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
    Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
    Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
    Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
    Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
    AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study.
    Kaira K; Oriuchi N; Shimizu K; Ishikita T; Higuchi T; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Int J Cancer; 2009 Mar; 124(5):1152-60. PubMed ID: 19065657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
    Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
    Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Takinami H; Iwado Y; Satoh K; Ohkawa M
    J Nucl Med; 2006 Oct; 47(10):1571-6. PubMed ID: 17015889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schwannoma of the extremities: the role of PET in preoperative planning.
    Ahmed AR; Watanabe H; Aoki J; Shinozaki T; Takagishi K
    Eur J Nucl Med; 2001 Oct; 28(10):1541-51. PubMed ID: 11685498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of 18F-fluorodeoxyglucose-PET in the diagonosis and monitoring of pulmonary sarcoidosis: a case report].
    Kaneko M; Tomioka H; Kaneda T; Kubot M; Tani S; Fujii H; Katsuyama E; Okazaki M
    Nihon Kokyuki Gakkai Zasshi; 2008 Jun; 46(6):505-9. PubMed ID: 18593000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
    Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
    J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.
    Miyakubo M; Oriuchi N; Tsushima Y; Higuchi T; Koyama K; Arai K; Paudyal B; Iida Y; Hanaoka H; Ishikita T; Nakasone Y; Negishi A; Mogi K; Endo K
    Ann Nucl Med; 2007 Feb; 21(2):129-35. PubMed ID: 17424980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the features of fluorine-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) between IgG4-related disease with bilateral hilar lymphadenopathy and sarcoidosis.
    Ozawa Y; Yamamoto H; Yasuo M; Komatsu M; Ushiki A; Hamano H; Uehara T; Kawakami S; Fujita A; Fujinaga Y; Oguchi K; Kawa S; Hanaoka M
    Nagoya J Med Sci; 2020 Feb; 82(1):101-111. PubMed ID: 32273638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
    Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I
    J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.
    Kaira K; Oriuchi N; Shimizu K; Ishikita T; Higuchi T; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Cancer Sci; 2009 Apr; 100(4):753-8. PubMed ID: 19141127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.
    Okumura W; Iwasaki T; Toyama T; Iso T; Arai M; Oriuchi N; Endo K; Yokoyama T; Suzuki T; Kurabayashi M
    J Nucl Med; 2004 Dec; 45(12):1989-98. PubMed ID: 15585472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET for esophageal cancer complicated by sarcoidosis mimicking mediastinal and hilar lymph node metastases: two case reports.
    Takanami K; Kaneta T; Yamada T; Kinomura S; Yamada S; Fukuda H; Takahashi S
    Clin Nucl Med; 2008 Apr; 33(4):258-61. PubMed ID: 18356663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.
    Beer AJ; Lorenzen S; Metz S; Herrmann K; Watzlowik P; Wester HJ; Peschel C; Lordick F; Schwaiger M
    J Nucl Med; 2008 Jan; 49(1):22-9. PubMed ID: 18077538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contingent diagnosis of sarcoidosis by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) after completion of chemotherapy for malignant lymphoma].
    Iino M; Iizuka C
    Rinsho Ketsueki; 2012 May; 53(5):540-2. PubMed ID: 22728558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.